Mohs Surgery for Skin Cancer: What It Is, Why Doctors Recommend It, and What to Expect on the Day

Research-informed explainer — last updated April 12, 2026

Mohs micrographic surgery is the most tissue-sparing, highest-cure-rate treatment available for basal cell carcinoma and squamous cell carcinoma in high-risk locations — achieving 5-year cure rates of 98–99% for primary tumors while preserving the maximum amount of surrounding healthy skin. For tumors on the face, ears, nose, and eyelids, where every millimeter matters cosmetically and functionally, Mohs is frequently the standard of care.

This article draws on research from five dermatologists and dermatologic surgeons. Dr. John Zitelli of Allegheny General Hospital in Pittsburgh co-authored the foundational studies on surgical margins for squamous cell carcinoma (533 citations), cost-effectiveness of Mohs surgery (267 citations), and Mohs micrographic surgery for primary cutaneous melanoma (247 citations). Dr. Murad Alam, Vice Chair of Dermatology and Chief of Cutaneous and Aesthetic Surgery at Northwestern, contributed the NEJM review of cutaneous squamous cell carcinoma (1,290 citations) and AAD guidelines for both SCC (555 citations) and basal cell carcinoma (471 citations). Dr. Timothy Berger of UCSF co-authored the 2012 multi-society Appropriate Use Criteria for Mohs surgery (525 citations) — the document that defines which tumors should be referred for Mohs versus standard excision. Dr. Anthony Oro of Stanford contributed landmark Science and Nature Medicine papers on the Sonic Hedgehog pathway that drives BCC development. Dr. Eleni Linos of Stanford quantified the risk of non-melanoma skin cancer from indoor tanning (348 citations) and published 5-year recurrence data following standard excision.

What Mohs surgery is — and what makes it different

Mohs surgery was developed by Dr. Frederic Mohs in the 1930s and refined into its current form in the 1970s. The defining feature is real-time histologic margin control: the surgeon removes a thin layer of tissue, processes and examines 100% of the surgical margins under the microscope on the same day, then returns for additional tissue removal only in the exact areas where cancer cells are still present.

Standard excision, by contrast, sends tissue to a pathology lab for next-day results and typically examines only a small sampling of the margins — a "bread-loafing" method that may miss positive edges. Mohs processes the entire undersurface and peripheral margins as a continuous map, making it almost impossible to leave residual cancer behind.

This distinction explains the cure rate difference: for primary BCC, Mohs achieves 5-year cure rates of approximately 99% versus 92–95% for standard excision. For recurrent BCC — tumors that have come back after prior treatment — Mohs achieves approximately 95% cure versus 60–80% for re-excision.

Which cancers are treated with Mohs

Mohs is most widely used for:

Basal cell carcinoma (BCC): The most common human cancer. Oro's 1997 Science paper (716 citations) established that constitutive Sonic Hedgehog pathway activation drives BCC development — explaining why BCCs arise preferentially in sun-exposed areas, grow slowly, and rarely metastasize but can cause extensive local destruction. Alam's 2018 AAD BCC guidelines (471 citations) recommend Mohs for high-risk tumors: those on the face (H-zone: nose, ears, lips, periorbital), large tumors (>2 cm on trunk), aggressive histologic subtypes (morpheaform, infiltrative, micronodular), and recurrent tumors.

Squamous cell carcinoma (SCC): The second most common skin cancer and the type that can metastasize. Alam's 2001 NEJM review (1,290 citations) established that SCC carries a 2–5% metastasis rate for standard tumors, rising to 25–45% for tumors arising in scars, radiation sites, or immunosuppressed patients. The 2018 AAD SCC guidelines (555 citations) recommend Mohs for high-risk features including tumors on the face, ear, scalp, hands, and genitalia, and those with perineural invasion or recurrence.

Zitelli's 1992 JAAD study (533 citations) established that standard surgical margins for SCC depend on tumor size and differentiation: well-differentiated tumors smaller than 2 cm can often be excised with 4 mm margins, while larger or poorly differentiated tumors require at least 6 mm for 95% tumor clearance — a finding that reinforced the case for Mohs in borderline tumors where margin precision matters most.

The 2012 Appropriate Use Criteria (AUC) co-authored by Berger (525 citations) from the AAD, ACMS, ASDSA, and ASMS jointly defined over 270 clinical scenarios rating Mohs as appropriate, uncertain, or inappropriate. This framework is now used by insurance plans to determine coverage and by physicians to guide referral decisions.

When Mohs is — and is not — the right choice

Mohs is appropriate when:

• The tumor is on a cosmetically or functionally sensitive location (face, ears, hands, genitalia, feet)
• The tumor is large (>2 cm), aggressive histologic subtype, or previously treated (recurrent)
• The tumor is in a patient who is immunosuppressed (transplant recipient, on biologic therapy)
• Tissue conservation is critical — e.g., tumor near the eye or on the lip

Mohs may not be needed for:

• Small, well-defined, low-risk BCCs on the trunk or extremities where standard excision has adequate cure rates
• Tumors where reconstruction would not be affected by taking a slightly wider margin

Linos's 2012 Journal of Investigative Dermatology study (179 citations) found that 5-year recurrence rates after standard excision were approximately 4.2% for BCC and 7.4% for SCC — numbers that, while acceptable for low-risk tumors, support Mohs referral when recurrence would have serious consequences for function or appearance.

What to expect on the day of Mohs surgery

Mohs surgery is performed as an outpatient procedure in a dermatologic surgery office — not an operating room. Plan to spend most of the day.

Before the procedure:

• Stop blood thinners only if your surgeon and prescribing physician agree it is safe to do so — most Mohs surgeons prefer to continue anticoagulants and manage bleeding locally rather than risk cardiac or stroke events from stopping medications
• Eat breakfast and take your regular medications unless instructed otherwise
• Bring something to read or listen to; waiting periods between stages can last 1–3 hours

During the procedure:

1. The surgeon injects local anesthetic (lidocaine). The injection is the most uncomfortable part; the procedure itself is painless.
2. The surgeon removes a thin saucer-shaped layer of tissue with a small margin around the visible tumor.
3. The excised tissue is color-coded, mapped, and processed into frozen sections that are examined under the microscope — usually taking 45–90 minutes.
4. If cancer cells are present at any margin, the surgeon returns and removes additional tissue from that specific area only. This cycle repeats until all margins are clear.
5. Once clear margins are confirmed, the wound is repaired — either primarily (closing the wound), with a skin flap, or a skin graft, depending on size and location.

Most tumors are cleared in one or two stages. Complex or large tumors may require three or four stages. Zitelli's 1998 JAAD cost analysis (267 citations) found that despite higher per-procedure costs compared to standard excision, the superior cure rates and tissue conservation of Mohs made it cost-effective for high-risk tumors — particularly because recurrence treatment is substantially more expensive and morbid.

Sun exposure and risk reduction

Linos's 2012 BMJ meta-analysis (348 citations) quantified that indoor tanning raises the risk of SCC by approximately 67% and BCC by 29%. Cumulative UV exposure — including occupational outdoor exposure — is the primary modifiable risk factor for both tumor types. After Mohs surgery, patients remain at elevated lifetime risk for additional skin cancers and should maintain sun protection and annual full-body skin exams.

Questions to ask your doctor

• Is my tumor on a location or of a histologic subtype that makes Mohs the recommended approach, or would standard excision be equally effective?
• How many stages should I plan for, and what is the likely size of the final wound?
• Do you perform the reconstruction yourself on the same day, or will I need to see a plastic surgeon separately?
• Should I stop aspirin, warfarin, or other blood thinners before the procedure?
• What will the scar look like, and are there options to minimize it?
• How often should I come back for surveillance skin checks going forward?

The bottom line

Mohs micrographic surgery achieves cure rates of 98–99% for primary basal cell carcinoma and is the standard of care for skin cancers in cosmetically sensitive or functionally critical locations. Its defining advantage — real-time examination of 100% of surgical margins — eliminates guesswork about whether the tumor has been completely removed. For appropriately selected patients, the same-day tissue processing means you leave knowing the cancer is gone, not waiting for a pathology report that may reveal incomplete margins requiring a second procedure.